CA2607561C - Composition pharmaceutique - Google Patents

Composition pharmaceutique Download PDF

Info

Publication number
CA2607561C
CA2607561C CA2607561A CA2607561A CA2607561C CA 2607561 C CA2607561 C CA 2607561C CA 2607561 A CA2607561 A CA 2607561A CA 2607561 A CA2607561 A CA 2607561A CA 2607561 C CA2607561 C CA 2607561C
Authority
CA
Canada
Prior art keywords
therapeutically active
carvacrol
fluconazole
substance
antifungal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2607561A
Other languages
English (en)
French (fr)
Other versions
CA2607561A1 (fr
Inventor
Adnane Remmal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Scientific Developments
Original Assignee
Advanced Scientific Developments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scientific Developments filed Critical Advanced Scientific Developments
Publication of CA2607561A1 publication Critical patent/CA2607561A1/fr
Application granted granted Critical
Publication of CA2607561C publication Critical patent/CA2607561C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2607561A 2005-05-13 2006-05-15 Composition pharmaceutique Expired - Fee Related CA2607561C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2005/001317 2005-05-13
PCT/IB2005/001317 WO2006120496A1 (fr) 2005-05-13 2005-05-13 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol
PCT/IB2006/001329 WO2006120565A2 (fr) 2005-05-13 2006-05-15 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol, et les i0n0nes alpha- et beta-.

Publications (2)

Publication Number Publication Date
CA2607561A1 CA2607561A1 (fr) 2006-11-16
CA2607561C true CA2607561C (fr) 2014-02-04

Family

ID=35427301

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2607561A Expired - Fee Related CA2607561C (fr) 2005-05-13 2006-05-15 Composition pharmaceutique

Country Status (13)

Country Link
US (1) US20080214568A1 (enExample)
EP (1) EP1879654B1 (enExample)
JP (1) JP5410747B2 (enExample)
CN (1) CN101189044B (enExample)
BR (1) BRPI0610132B8 (enExample)
CA (1) CA2607561C (enExample)
DK (1) DK1879654T3 (enExample)
EA (1) EA014068B1 (enExample)
ES (1) ES2390472T3 (enExample)
MA (1) MA29907B1 (enExample)
PT (1) PT1879654E (enExample)
TN (1) TNSN07425A1 (enExample)
WO (2) WO2006120496A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2581507C (en) 2004-09-28 2013-09-10 Chemaphor Inc. Compositions and methods for promoting weight gain and feed conversion
ES2716474T3 (es) 2007-10-26 2019-06-12 Avivagen Inc Composiciones y métodos para mejorar la respuesta inmunitaria
WO2010124391A1 (en) 2009-04-30 2010-11-04 Chemaphor Inc. Methods and compositions for improving the health of animals
EA019746B1 (ru) 2009-09-24 2014-05-30 Юнилевер Нв Противомикробная композиция, содержащая эвгенол, терпинеол и тимол, и способ дезинфицирования поверхности
CN103354741B (zh) 2010-12-07 2016-01-13 荷兰联合利华有限公司 口腔护理组合物
CN102550610B (zh) * 2010-12-07 2014-12-10 菲勒斯株式会社 含有从红松球果中提取的植物杀菌素的天然抗菌剂及包含它的水果病害防除原料
EP2672845A2 (en) * 2011-02-07 2013-12-18 Firmenich SA Antifungal flavouring ingredients and compositions
EP2773315B1 (en) 2011-11-03 2015-07-08 Unilever N.V. A personal cleaning composition
JP5925605B2 (ja) * 2012-06-04 2016-05-25 花王株式会社 リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
IL251588B2 (en) 2014-10-08 2024-09-01 Pacific Northwest Res Institute Methods and compositions for increasing the potency of antifungal agents
CN104642326B (zh) * 2015-02-16 2016-02-10 河南科技学院 一种含戊苯吡菌胺和香芹酚的杀菌组合物及其用途
US11872216B2 (en) 2016-06-02 2024-01-16 Advanced Scientific Developments Pharmaceutical formulation comprising cineole and amoxicillin
ES2937307T3 (es) 2016-07-26 2023-03-27 Univ Southern California Inhibición selectiva del bromodominio del BDF1 fúngico
CN113116916B (zh) * 2021-05-25 2023-07-04 河北医科大学第二医院 一种治疗妇科疾病的药物组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294645A (en) * 1993-06-14 1994-03-15 Doyle E. Chastain Using menth-1-en-9-ol to kill bacteria, yeast, and fungi
CA2106032C (en) * 1993-09-13 1995-11-07 Gamini Weeratunga Methods for the manufacture of fluconazole and forms thereof, intermediates useful in the manufacture thereof, and combinations comprising fluconazole
ATE215379T1 (de) * 1994-01-14 2002-04-15 Xoma Technology Ltd Antifungaleverfahren und mitteln
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6319507B1 (en) * 1997-05-02 2001-11-20 Kobo Products, Inc. Agar gel bead composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
WO2002056879A1 (en) * 2001-01-03 2002-07-25 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
JP2002284702A (ja) * 2001-01-19 2002-10-03 Teika Seiyaku Kk 外用抗真菌製剤
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
JP2002363070A (ja) * 2001-06-06 2002-12-18 Yuutoku Yakuhin Kogyo Kk 経皮吸収貼付剤
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
EP1455768A1 (en) * 2001-12-07 2004-09-15 Eden Research Plc Respiratory infection prevention and treatment with terpene-containing compositions
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US20050014730A1 (en) * 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil

Also Published As

Publication number Publication date
ES2390472T3 (es) 2012-11-13
BRPI0610132A2 (pt) 2012-09-25
JP5410747B2 (ja) 2014-02-05
WO2006120565A3 (fr) 2007-08-23
WO2006120496A1 (fr) 2006-11-16
US20080214568A1 (en) 2008-09-04
BRPI0610132B1 (pt) 2020-08-11
BRPI0610132B8 (pt) 2021-05-25
MA29907B1 (fr) 2008-11-03
CA2607561A1 (fr) 2006-11-16
EP1879654A2 (fr) 2008-01-23
DK1879654T3 (da) 2012-08-20
TNSN07425A1 (fr) 2009-03-17
WO2006120565A2 (fr) 2006-11-16
EA014068B1 (ru) 2010-08-30
EP1879654B1 (fr) 2012-07-04
CN101189044B (zh) 2011-12-07
CN101189044A (zh) 2008-05-28
PT1879654E (pt) 2012-08-29
EA200702482A1 (ru) 2008-04-28
JP2008540506A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
CA2607561C (fr) Composition pharmaceutique
BE1011370A5 (fr) Nouvelle association parasiticide.
CA2606875C (fr) Combinaison pharmaceutique comprenant un antibiotique et une substance active choisie parmi le carveol, le thymol, le carvacrol, l'alpha-ionone et beta-ionone
EP1879656B1 (fr) Composition pharmaceutique comprenant un antitumoral et un actif choisi notamment parmi le carveol , le thymol et le carvacrol
EP3429611B1 (fr) Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique
WO2021099453A1 (fr) Extrait liquide aqueux de spiruline pour la prévention et/ou le traitement des neuropathies périphériques chimio-induites et leurs symptômes, composition et utilisation correspondantes
EP3463479A2 (fr) Formulation pharmaceutique de cinéol et d'amoxicilline
EP3193936A1 (fr) Antimicrobiens potentialises
EP0771187B1 (fr) Nouveau produit de combinaison comprenant un agent antifongique et du crotamiton comme potentialisateur de l'activite de l'agent antifongique, et compositions dermatologiques et/ou cosmetiques le comprenant
EP3377061A1 (fr) Mirabégron pour le traitement de maladies rétiniennes
EP2214789A2 (fr) Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
WO2017017091A1 (fr) Nouvelles compositions vétérinaires pour la prévention et le traitement simultané des endoparasites et ectoparasites
FR2609714A1 (fr) Compositions liquides stables a base de derives antifongiques imidazoles
FR3052066B1 (fr) Formulation pharmaceutique de cineol et d'amoxicilline
WO2017158282A1 (fr) Tulathromycine potentialisee
FR3092490A1 (fr) Composé aminostéroïdien analogue de la squalamine pour son utilisation dans le traitement et / ou la prévention d’une dermatophytose

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210517